Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate

Loading...
Loading...

Kezar Life Sciences, Inc. KZR reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN).

The MISSION Phase 2 clinical trial study is designed to demonstrate the responder rate of zetomipzomib in patients with active lupus nephritis (LN).

In the Phase 2 topline analysis, 17 of 21 patients enrolled in the trial reached end of treatment, while 11 of 17 patients (64.7%) achieved an ORR measured as a 50% or greater reduction in UPCR at EOT compared to baseline, the primary efficacy endpoint of the clinical trial.

The company said that Zetomipzomib continues to demonstrate a favorable safety and tolerability profile for administration over the 6-month treatment period.

Noreen R. Henig, M.D., Kezar's Chief Medical Officer, commented : ”The MISSION Phase 2 topline results show a clinically meaningful overall renal response to zetomipzomib after 6 months, without high-dose induction therapy. Patients in the trial also experienced reductions in extra-renal manifestations of lupus. Zetomipzomib appears to be immunomodulatory, well-tolerated and steroid-sparing – all important attributes for patients with autoimmune disease who are often young and active.”

Shares of Kezar Life Sciences are trading high 106 percent at $11.90 during after-hour session.

Loading...
Loading...
Posted In: BiotechHealth CareMovers & ShakersSmall CapGeneralTopline Results
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...